Peptidyl Anthraquinones as Potential Antineoplastic Drugs: Synthesis, DNA Binding, Redox Cycling, and Biological Activity
- 1 January 1996
- journal article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 39 (16), 3114-3122
- https://doi.org/10.1021/jm950924a
Abstract
A series of new compounds containing a 9,10-anthracenedione moiety and one or two peptide chains at position 1 and/or 4 have been synthesized. The amino acid residues introduced are glycine (Gly), lysine (Lys), and tryptophan (Trp), the latter two in both the l- and d-configurations. The peptidyl anthraquinones maintain the ability of intercalating efficiently into DNA, even though the orientation within the base-pair pocket may change somewhat with reference to the parent drugs mitoxantrone (MX) and ametantrone (AM). The interaction constants of the mono-, di-, and triglycyl derivatives are well comparable to those found for AM but 5−10 times lower than the value reported for MX. On the other hand, the glycyl-lysyl compounds bind DNA to the same extent as (l-isomer) or even better than (d-isomer) MX. As for the parent drugs without peptidyl chains, the new compounds prefer alternating CG binding sites, although to different extents. The bis-Gly-Lys derivatives are the least sensitive to base composition, which may be due to extensive aspecific charged interactions with the polynucleotide backbone. As far as redox properties are concerned, all peptidyl anthraquinones show a reduction potential very close to that of AM and 60−80 mV less negative than that of MX; hence, they can produce free-radical-damaging species to an extent similar to the parent drugs. The biological activity has been tested in human tumor and murine leukemia cell lines. Most of the test anthraquinones exhibit cytotoxic properties close to those of AM and considerably lower than those of MX. Stimulation of topoisomerase-mediated DNA cleavage is moderately present in representatives of the glycylanthraquinone family, whereas inhibition of the background cleavage occurs when Lys is present in the peptide chain. For most of the test anthraquinones, the toxicity data are in line with the DNA affinity scale and the topoisomerase II stimulation activity. However, in the lysyl derivatives, for which lack of cytotoxicity cannot be related to poor binding to DNA, the steric and electronic properties of the side-chain substituent must impair an effective recognition of the cleavable complex.Keywords
This publication has 21 references indexed in Scilit:
- Conformational properties of topoisomerase II inhibitors and sequence specificity of DNA cleavageJournal of Molecular Recognition, 1994
- Conformational Drug Determinants of the Sequence Specificity of Drug-stimulated Topoisomerase II DNA CleavageJournal of Molecular Biology, 1994
- New hydroxy-amido-anthraquinones as potential antineoplastic drugs.Bioorganic & Medicinal Chemistry Letters, 1992
- Novel Gabriel reagentsAccounts of Chemical Research, 1991
- Redox Cycling in MCF-7 Human Breast Cancer Cells by Antitumor Agents Based on MitozantroneFree Radical Research Communications, 1989
- Diethylaminopropionamido‐hydroxy‐anthraquinones as Potential Anticancer Agents : Synthesis and CharacterizationArchiv der Pharmazie, 1989
- 9‐Acridinylpeptides and 9‐acridinyl‐4‐nitrophenylsulfonylpeptidesInternational Journal of Peptide and Protein Research, 1988
- Isolation of intercalator-dependent protein-linked DNA strand cleavage activity from cell nuclei and identification as topoisomerase IIBiochemistry, 1986
- New anthracenedione derivatives: Interaction with DNA and biological effectsChemico-Biological Interactions, 1983
- Synthesis of 3,4-dihydro-4-oxothieno[2,3-d]pyrimidine-2-carboxylates, a new series of orally active antiallergy agentsJournal of Medicinal Chemistry, 1979